Education

1989 Master, Neurology, Capital Medical University

1982 Bachelor, Clinical Medicine, Hebei Medical College

 

Academic Experience

2000-present   Vice President, Executive Vice President, President, Beijing Tiantan Hospital, Capital Medical University   

1999-2000       Postdoctor, Arkansas Medical University

Overview of Academic Research

Prof. Yongjun Wang has long been engaged in applied basic and translational medical research of cerebrovascular disease, and has accomplished a series of original academic achievements. He has created the short-term, dual-channel, dual-effect combined therapy protocol for ischemic cerebrovascular disease, solved the international clinical problem of combined antiplatelet therapy,    rewritten international guidelines and changed clinical practice. He has revealed the genetic characteristics of the efficacy of combined drugs for cerebrovascular disease and established a precision medicine protocol. He has also created a new strategy to promote the translation of guidelines into clinical practice, and developed innovative drugs for new targets. He has published more than 300 papers as the corresponding author including 2 in NEJM, 2 in JAMA, 1 in BMJ, and 4 in Circulation, which have been cited over 5000 times. He has been invited twice to write reviews for BMJ. He has presided over the introduction of two industry standards and seven professional guidelines, and served as the strategic planning panel leader of the “12th Five-Year Plan” for cerebrovascular disease, “13th Five-Year Plan” for major chronic disease, and “14th Five-Year Plan” for common frequently-occurring disease of the Ministry of Science and Technology. He is also a member of the expert group of National Major Scientific and Technological Special Project for “Significant New Drugs Development” and 2030 technological innovation major project for “Brain Science and Brain-Like Intelligence Technology”. He is the chairman of the Neurology Branch of the Chinese Medical Association and the president of the Chinese Stroke Association. 

Major Honor and Awards

He has been nominated as“Beijing Scholar” and "Beijing High-level innovating and entrepreneurial talent support program outstanding talent”. He has won 2 Second Prize of National Science and Technology Progress Awards and 2 First Prize of Ministerial and Provincial-Level Science and Technology Progress Awards as the first person to complete. He has received the First National Innovation Awards Medal, “Wu Jieping Medical & Pharmaceutical Innovation Award”, the 13th “Tan Jiazhen Life Science Clinical Medicine Award”, “Ho Leung Ho Lee Foundation's Science and Technology Progress Award” and the World Stroke Organization President's Award. He has led his research team to win the title of the first batch of excellent innovation team in critical research fields of the Ministry of Science and Technology.

In February 2020, he was selected into the National Health Science Popularization Expert Database.

In 2020, he became a member of the Academic Department of Chinese Academy of Medical Sciences.

Representative Research Achievements 

1.  Wang Y*, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B; CHANCE-2 Investigators. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. NEW ENGL J MED, 2021.385(27).2520-2530.

2.  Wang Y*, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC*; THALES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA NEUROL, 2021.78(9).1091-1098.

3.  Wang, Y.* Johnston, S. C. Bath, P. M. Grotta, J. C. Pan, Y. Amarenco, P. Wang, Y. Simon, T. Kim, J. S. Jeng, J. S. Liu, L. Lin, Y. Wong, K. S. L. Wang, D. Li, H. Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ, 2019.364.1895.

4.  Pan, Y. Chen, W. Wang, Y. Li, H. Johnston, S. C. Simon, T. Zhao, X. Liu, L. Wang, D. Meng, X. Wang, Y.* Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol, 2019.76 (5).552-560.

5.  Pan, Y. Elm, J. J. Li, H. Easton, J. D. Wang, Y. Farrant, M. Meng, X. Kim, A. S. Zhao, X. Meurer, W. J. Liu, L. Dietrich, D. Wang, Y.* Johnston, S. C.* Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol, 2019.76 (12).1466-1473.

6.  Wang, Y.#* Chen, W.# Lin, Y. Meng, X. Chen, G. Wang, Z. Wu, J. Wang, D. Li, J. Cao, Y. Xu, Y. Zhang, G. Li, X. Pan, Y. Li, H. Zhao, X. Liu, L. Lin, J. Dong, K. Jing, J. Johnston, S. C. Wang, D. Wang, Y.* Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ, 2019.365.12211.

7.  Wang, Y. Li, Z. Zhao, X. Wang, C. Wang, X. Wang, D. Liang, L. Liu, L. Wang, C. Li, H. Shen, H. Bettger, J. Pan, Y. Jiang, Y. Yang, X. Zhang, C. Han, X. Meng, X. Yang, X. Kang, H. Yuan, W. Fonarow, G. C. Peterson, E. D. Schwamm, L. H. Xian, Y. Wang, Y.* Golden Bridge-Ais Investigators. Effect of a Multifaceted Quality Improvement Intervention on Hospital Personnel Adherence to Performance Measures in Patients With Acute Ischemic Stroke in China A Randomized Clinical Trial. JAMA, 2018.320(3).245-254.

8.  Wang Y., Zhao X., Lin J., Li H., Johnston S. C., Lin Y., Pan Y., Liu L., Wang D., Wang C., Meng X., Xu J., Wang Y*. Association between cyp2c19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke o r transient ischemic attack. JAMA, 2016.316(1).70-8.

9.  Wang Y., Wang Y., Zhao X., Liu L., Wang D., Wang C., Wang C., Li H., Meng X., Cui L., Jia J., Dong Q., Xu A., Zeng J., Li Y., Wang Z., Xia H., Johnston S. C., the Chance Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 2013. 369(1).11-19.